Eligible adult women with newly diagnosed ovarian cancer that was either high-risk early-stage disease ( International Federation of Gynecology and Obstetrics -LSB- FIGO -RSB- stage I-IIa , grade @ or clear cell histology ) or more advanced disease ( FIGO stage IIb-IV ) , with an Eastern Cooperative Oncology Group performance status of @-@ , were enrolled and randomly assigned in a @:@ ratio to standard chemotherapy ( six @-weekly cycles of intravenous carboplatin -LSB- AUC @ or @ -RSB- and paclitaxel @ mg/m ( @ ) of body surface area ) or the same chemotherapy regimen plus bevacizumab @ mg per kg bodyweight intravenously every @ weeks , given concurrently and continued with up to @ further @-weekly cycles of maintenance therapy .